Bio-Techne Launches Simple Plex Platform

News provided by

Jan 22, 2015, 04:15 ET

MINNEAPOLIS, Jan. 22, 2015 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced today that it has launched Ella, the first member of the new Simple Plex platform through its Proteins Platform division under the ProteinSimple brand. This launch represents the re-branding of the previously acquired CyPlex instrument platform from CyVek.

The Simple Plex platform is a transformative immunoassay technology which integrates an innovatively designed microfluidic cartridge with a state-of-the-art analyzer to deliver the most efficient benchtop immunoassay system along with reliable results. It brings a level of automation to the traditional ELISA by providing "sample-to-answer" test results in a sealed disposable cartridge within 1 hour while removing operator related biases. In addition, because of its unique multi-analyte capability with none of the drawbacks of traditional multiplex platforms, this platform has broad applicability in both research and clinical markets. We believe the Simple Plex technology, along with other immunoassay platforms offered by Bio-Techne, represent the most comprehensive line of immunoassay products to meet customers' complete workflow in their research and clinical protein applications.

Bio-Techne is a leading developer and manufacturer of purified proteins, notably cytokines and growth factors, antibodies, immunoassays and biologically active small molecule compounds which are sold to biomedical researchers and clinical research laboratories throughout the world. San Jose, California-based ProteinSimple develops and commercializes proprietary systems and consumables that simplify protein analysis. The Simple Plex platform will join other innovative instrument platforms which include instruments for automated Western blot analysis, devices for isoelectric focusing of proteins and protein particle analysis. The Simple Plex platform will be manufactured and further developed by ProteinSimple while leveraging the extensive reagent portfolio from Bio-Techne primarily through the R&D Systems brand.

Chuck Kummeth, President and CEO of Bio-Techne, commented, "Ella is a great technology addition to the ProteinSimple family. Meeting our customers' expectations during their workflow is consistent with our long term goal of providing increasingly more complete workflow solutions to investigators. The ability to include the highly valued Bio-Techne reagent content on the Simple Plex platform, along with our assay development know-how, is one of the most appealing aspects of this technology."

Bio-Techne Corporation, NASDAQ: TECH, is a global life sciences company providing innovative bioactive tools and resources for the research and clinical diagnostic communities. Bio-Techne products assist and enable scientific investigations into biological processes and further the knowledge of specific pathologies and disease processes. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With over 250,000 products in its current portfolio and over 1,300 employees worldwide, Bio-Techne generated approximately $358 million in net sales in fiscal 2014. For more information on Bio-Techne and its brands, please visit us online at: www.bio-techne.com.

Forward-Looking Statements

Certain statements found in this release may constitute forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect the speaker's current views with respect to future events and financial performance and include any statement that does not directly relate to a current or historical fact. Forward-looking statements can generally be identified by the words "believe," "expect," "anticipate" or "intend" or similar words. The following important factors, among others, have affected and, in the future, could affect the Company's actual results: the effect of new branding and marketing initiatives, the integration of new leadership, the introduction and acceptance of new biotechnology and clinical control products, the levels and particular directions of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships.

For additional information concerning such factors, see the section titled "Risk Factors" in the Company's annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements we make in our press releases due to new information or future events. Investors are cautioned not to place undue emphasis on these statements.

SOURCE Bio-Techne Corporation